TNFRSF8 and lymphoma: Nakashima and Uchimaru [29] highlighted the promising clinical outcomes of antibody‒drug conjugates (ADCs) targeting CD30 in managing lymphomas with CD30 overexpression, emphasizing the critical role of CD30 signaling in promoting chromosomal instability, which is crucial for ALCL progression.